(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 4.32% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Zoetis's revenue in 2025 is $9,385,000,000.On average, 8 Wall Street analysts forecast ZTS's revenue for 2025 to be $4,216,723,655,911, with the lowest ZTS revenue forecast at $4,188,526,993,872, and the highest ZTS revenue forecast at $4,230,855,447,283. On average, 8 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,469,553,178,935, with the lowest ZTS revenue forecast at $4,404,844,846,555, and the highest ZTS revenue forecast at $4,538,441,174,639.
In 2027, ZTS is forecast to generate $4,722,345,917,731 in revenue, with the lowest revenue forecast at $4,575,426,164,928 and the highest revenue forecast at $4,889,534,666,625.